Clinical Significance of Anti‐Ata

G. Ramsey*, L. A. Sherman, A. M. Zimmer, W. G. Spies, L. Sharma, P. Arndt, G. Garratty

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Ata is a high‐frequency red blood cell (RBC) antigen. Anti‐Ata has been reported in rare At(a–) black subjects. We report two cases of anti‐Ata. A clinically significant anti‐Ata was found in a 26‐year‐old black woman with systemic lupus erythematosus. The patient had a transfusion reaction with chills and nausea during a RBC survival study, and 95% of the radiolabeled At(a+) RBCs were destroyed within 3 h. A concurrently performed monocyte monolayer assay was strongly reactive. Anti‐Ata thus can cause rapid hemolysis of transfused RBCs, but At(a–) donor units are extremely scarce in rare donor registries. A second patient at our hospital had anti‐Ata which did not affect her newborn. She also had autoimmune disease, insulin‐dependent diabetes mellitus.

Original languageEnglish (US)
Pages (from-to)135-137
Number of pages3
JournalVox Sanguinis
Issue number2
StatePublished - Aug 1995

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Clinical Significance of Anti‐Ata'. Together they form a unique fingerprint.

Cite this